Marksans Pharma Ltd.

NSE: MARKSANS | BSE: 524404 | ISIN: INE750C01026 |Industry: Pharmaceuticals
|Mid-range Performer
58.05 1.15 (2.02%)
NSE Dec 03, 2021 15:31 PM
Volume: 1.4M
 

Marksans Pharma Ltd.    
10 Nov 2021
58.05
2.02%

Highlights:

  • Consolidated Q2 FY22 (YoY):
    • Operating Revenue was Rs. 361.2 Cr. as compared to Rs. 356.5 Cr. in Q2 FY21, an increase of 1.3% 
    • EBITDA was Rs. 60.1 Cr. as compared to Rs. 83.2 Cr. in Q2 FY21
    • EBITDA Margin stood at 16.6% as against 23.3% in Q2 FY21 
    • PAT stood at Rs. 46.3 Cr. as compared to Rs. 50.7 Cr. in Q2 FY21 
  • Consolidated H1 FY22 (YoY):
    • Operating Revenue was Rs. 710.2 Cr. as compared to Rs. 687.6 Cr. in H1 FY21, an increase of 3.3% 
    • EBITDA was Rs. 137.4 Cr. as compared to Rs. 153.2 Cr. in H1 FY21
    • EBITDA Margin stood at 19.0% as against 22.2% in H1 FY21 
    • PAT stood at Rs.108.9 Cr. as compared to Rs. 100.1 Cr. in H1 FY21, an increase of 8.8%
Commenting on the performance Mark Saldanha, Managing Director of the Company said “We had a challenging half year with geopolitical issues impacting shipments and inputs. Our revenue growth of 3.3 percent in H1FY22 was driven by the increasing penetration in EU and North American markets. Higher raw material, freight and packaging costs impacted margins however reduced finance costs and lower tax outgo helped to neutralise the same resulting us grow our bottomline by 8.8% in H1FY22. We remain focused on delivering superior returns for the long term to all our stake holders.” 

 

 

Result PDF

default
Marksans Pharma Ltd. is trading below all available SMAs
Recommended
More from Marksans Pharma Ltd.